AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06031428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MANAGe-DM - novel nurse case management
Description: Participants assigned to MANAGe-DM will receive the standard diabetes education mailing in addition to a novel nurse case management intervention. Each month of the study period, the NCM will conduct two phone call intervention sessions with individual participants.
Study NCT06031428 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monthly Educational Mailing
Description: All participants in the study will receive diabetes education mailers. This includes monthly mailings of diabetes education, based off the American Diabetes Association guidelines for Diabetes Education. Topics covered will include diabetes basics, monitoring and medications, healthy eating and exercise, overview of common comorbidities, basics of foot care, and strategies for overcoming common pitfalls.
Study NCT04909931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D 2
Description: Randomized allocation first arm : add on vitamin D supplementation 40,000 iu/week for 12 weeks
Study NCT04909931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Second arm : add on placebo for 12 weeks
Study NCT06130449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natesto testosterone intranasal gel
Description: A single dose of Natesto (11 mg total, 5.5 mg per nostril) will be administered to each participant.
Study NCT06130449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ayr Saline Nasal Gel
Description: A single dose of Ayr (one spray per nostril) will be administered to each participant.
Study NCT05788783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery & Care Canine-Assisted Therapy
Description: Active intervention. An 6-week session of structured, goal-oriented activities where youth focus on mastering dog obedience and dog training skills. Each session is 1 hour and 15 minutes in length and includes education, review of prior sessions, and specific skill-building activities. Skill-building activities progress in complexity during the course of the 6-week curriculum.
Study NCT05788783 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Canine Education & Bonding
Description: Active control intervention. An 6-week session of semi-structured activities. Sessions are 45 minutes in length. Youth in this condition engage in an educational component, passive observation of dog-training skills, and an active free-play session with the dog-handler teams.
Study NCT05851378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG)
Description: Given intravenously at time of imaging
Study NCT05851378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Image (MRI)
Description: Magnetic resonance imaging is a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
Study NCT04959344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kleb4V target dose
Description: Two doses of the non-adjuvanted Kleb4V target dose will be administered intramuscularly 2 months apart
Study NCT04959344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kleb4V target dose + AS03
Description: Two doses of the adjuvanted Kleb4V target dose will be administered intramuscularly 2 months apart
Study NCT04959344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kleb4V low dose
Description: Two doses of the non-adjuvanted Kleb4V low dose will be administered intramuscularly 2 months apart
Study NCT04959344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kleb4V low dose + AS03
Description: Two doses of the adjuvanted Kleb4V low dose will be administered intramuscularly 2 months apart
Study NCT04959344 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two doses of the Placebo will be administered intramuscularly 2 months apart
Study NCT05076903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OFA
Description: Dexmedetomidine and lidocaine are administered during anesthesia, and opioid is not used. For induction, 1 μg/kg of Dexmedetomidine is administered over 10 minutes and 1mg/kg of lidocaine is administered intavenously (bolus). This is followed by continuous intravenous infusion of dexmedetomidine at a rate of 0.2-0.7 μg/kg/h and infusion of lidocaine at the rate of 1 mg/kg/h.
Study NCT05076903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Remifentanil is infused during anesthesia, and target-controlled infusion (TCI) is performed according to the Minto model. During indcution of anestheisa, target concentration of remifentanil is set within 3-5 ng/mL. After intubation, target concentration is adjusted within the range of 2-8 ng/mL.
Study NCT06499077 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sampling of exhaled breath
Description: Exhaled breath of all participants is collected following our standardized procedure
Study NCT04755504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EEG behind the ear
Description: 2 additional electrodes behind each ear will record EEG
Study NCT04877756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLX10010
Description: Lyophilized cake reconstituted with WFI and injected intradermally
Study NCT06497699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexycu
Description: single injection,5ul solution,concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone
Study NCT05064176 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Home physical therapist performs usual care and educates the patient to perform self-management~Usual care:~M1-6: 6 months of maintenance decongestive lymphatic therapy (DLT) (by patient and home physical therapist):~* week 1-2: no physical therapy; patient performs limb elevation, muscle contractions and wears the bandage (intervention group)/ compression garment (control group)~* week 3-4: start physical therapy, 2 days/ week: exercises, skin care \& manual lymph drainage (MLD), education; self-management by patient and wearing compression garment 14-16h/day (4 sessions) M2-6: 1 day/ week physical therapist: exercises, skin care \& MLD, and self-management by patient and wearing compression garment 14-16h/day (20 sessions)~M7-12: 6 months of maintenance DLT by patient (self-management) and home physical therapist:~- 1 day/week physical therapist: skin care, MLD, exercises (26 sessions) Month 13-18: 6 months of maintenance DLT by patient Month 19-36: 18 months of follow-up
Study NCT05064176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Home physical therapist performs usual care and educates the patient to perform self-management~Usual care:~M1-6: 6 months of maintenance decongestive lymphatic therapy (DLT) (by patient and home physical therapist):~* week 1-2: no physical therapy; patient performs limb elevation, muscle contractions and wears the bandage (intervention group)/ compression garment (control group)~* week 3-4: start physical therapy, 2 days/ week: exercises, skin care \& manual lymph drainage (MLD), education; self-management by patient and wearing compression garment 14-16h/day (4 sessions) M2-6: 1 day/ week physical therapist: exercises, skin care \& MLD, and self-management by patient and wearing compression garment 14-16h/day (20 sessions)~M7-12: 6 months of maintenance DLT by patient (self-management) and home physical therapist:~- 1 day/week physical therapist: skin care, MLD, exercises (26 sessions) Month 13-18: 6 months of maintenance DLT by patient Month 19-36: 18 months of follow-up
Study NCT05064176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstructive lymphatic surgery
Description: For the procedure of LVA:~- Aim: making anastomoses of lymph vessels at the capillary level with a diameter of 0.3 to 0.8 mm, to redirect lymph to venous stream directly~For the procedure of LNT:~- Aim:~1. Placed lymph nodes act as sponge to absorb lymphatic fluid and direct it into the vascular network;~2. Placed lymph nodes induce lymphangiogenesis
Study NCT05981001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery for harvesting tumor-draining lymph nodes
Description: A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
Study NCT05981001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 60 mg/kg IV daily over approximately two hours for two days. Cyclophosphamide will be initiated seven days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
Study NCT05981001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: After administration of cyclophosphamide, fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes for five days, starting five days prior to LNL transfer.
Study NCT05981001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-draining lymph node-derived lymphocyte (LNL)
Description: In the dose-escalation portion of phase I study, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion of phase I study, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).~In the phase II study, participants receive single infusion of LNL at the RP2D.
Study NCT05981001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
Study NCT05981001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab will be administered at a fixed dose of 200mg IV on Day 1 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study NCT05981001 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab
Description: Camrelizumab will be administered at a fixed dose of 200mg IV on Day 1 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study NCT05981001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered at 100 mg/m\^2 IV on Days 1, 8 and 15 of each 28-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study NCT04246008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular training
Description: The exercise training was developed based on assuring the correct performance of the exercise focusing in motor control.
Study NCT04246008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional strength training
Description: The exercise training was developed based on standard strength training used in cardiac rehabiliation programmes
Study NCT05981001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered at 100 mg/m\^2 IV on Days 1, 8 and 15 of each 28-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study NCT05981001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered at 1000 mg/m\^2 IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study NCT05981001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered at 1000 mg/m\^2 IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study NCT05981001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered at area under the concentration-time curve 2 (AUC 2) IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study NCT05981001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered at area under the concentration-time curve 2 (AUC 2) IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study NCT06439433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolaevulinic acid (500-mg bottle)
Description: once a week for 6 weeks
Study NCT06439433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolaevulinic acid (750-mg bottle)
Description: once a week for 6 weeks
Study NCT06439433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once a week for 6 weeks
Study NCT05504265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preemptive flurbiprofen axetil
Description: 50mg once，30min before induction anesthesia
Study NCT05504265 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Postoperative flurbiprofen axetil
Description: 50mg bid
Study NCT05564689 — intervention group
Intervention type: PROCEDURE
Intervention: Intracoronary flow and pressure
Description: Measurement of absolute coronary flow and resistance
Study NCT05504265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postoperative flurbiprofen axetil
Description: 50mg bid
Study NCT05504265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia pump
Description: Sufentanil 2.5 μg/kg+ondansetron 8mg, prepared to 100ml normal saline; background dose: 2 ml/h, single press analgesic pump injection volume: 0.5 ml, locking time: 15 min.
Study NCT04718168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gore ENFORM Biomaterial (Preperitoneal)
Description: ENFORM Biomaterial bioabsorbable hernia mesh
Study NCT06214130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium valproate 500 MG
Description: oral intake
Study NCT06214130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium valproate 500 MG
Description: oral intake
Study NCT06214130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid 500 MG
Description: oral intake
Study NCT06214130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid 500 MG
Description: oral intake
Study NCT05615272 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bio-PRF
Description: Intervention group
Study NCT05615272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alveogyl
Description: Control group
Study NCT05693779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise training
Description: Participants will complete an Exercise Treadmill Test at baseline. The 12 weeks exercise program that will be assigned to each patient will be based on these results. The exercise will be three 20-minute exercise sessions per week for 6 weeks. This will increase to four 60-minute exercise sessions per week at increased intensity progressively over the course of the exercise program. The exercise program will involve walking/jogging, elliptical training, or biking 3-4 times per week for up to an hour each session. If participants don't have access to a bike or elliptical, they will be asked to exercise by walking/jogging.~Participants will also a phone call or video chat that takes about 15 minutes per week to discuss the exercise program and take 2 short surveys weekly on the MyDataHelps application and filling out a logbook recording exercise sessions. In addition, participants activity will be measured by using a smartwatch during the study.
Study NCT04718168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gore ENFORM Biomaterial (Intraperitoneal)
Description: ENFORM Biomaterial bioabsorbable hernia mesh
Study NCT04669301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAAT-G
Description: Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies.
Study NCT04669301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive therapy (time and attention control)
Description: Supportive Therapy (ST) is a behavioral placebo and controls for non-specific psychotherapeutic factors of the clinician-subject relationship, such as empathy and support, but does not provide active cognitive training. ST utilizes reflective listening to help deepen awareness of participants' emotional experience. Timing and duration of ST sessions will mirror the intervention, and will consist of 10 weekly sessions, 30 to 45 minutes each, delivered by trained psychologists via video-conferencing.
Study NCT05538572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT3645
Description: PRT3645 capsules will be self-administered once daily, continuously, at the dose-level assigned
Study NCT06105736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention in a small group platform
Description: RT is small-group-based, intensive behavioral intervention session delivered twice weekly over a secure remote platform for 60-minutes over 5 weeks. Each session is led by a psychologist trained and certified in RT. Caregiver groups meet at the same frequency and duration but at different times. Each session has a specific focus for teaching participants to identify emotions and incorporation of cognitive behavioral therapy (CBT) and mindfulness skills that are reinforced through repeated practice. Each session will include a review, relaxation, new material didactic, activities to reinforce material, mindfulness, and homework.
Study NCT04939181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Neuromodulation
Description: The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents:~pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA.
Study NCT04939181 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Non-invasive Neuromodulation
Description: The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
Study NCT04901442 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aetrex L700 Speed orthotic
Description: An orthotic insole to be inserted into running shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain, and Metatarsalgia. Helps prevent injury, alleviate discomfort and helps reduce fatigue while running
Study NCT06479265 — intervention group
Intervention type: OTHER
Intervention: Phyical/Cognitve Exercise
Description: Participants will report to the CERC and review informed consent with a study investigator. Eligibility assessments (PAR-Q, WCST64, Medical History) will be done post-consent. Data collected will include age, body composition, gender, aerobic capacity, chronic medication use, and treated pathologies. All measurements will occur during one visit. Participants will lay supine for 5 minutes to measure resting heart rate (HR) using an HR monitor. This resting HR, with age-predicted HR max, will determine HR reserve (HRR). Participants will master the WCST64 and identify walking pace on the Blue Goji treadmill. They will complete a baseline 10 Meter Walk Test, followed by the digital WCST64 under 7 conditions, ending with a post-intervention 10 Meter Walk Test.
Study NCT06174688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular Injections
Study NCT05418114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: . One group (Group A) will be given local infiltration with 9 ml (180 mg) of 2% lignocaine + 1 ml (500 mg) of 50% Magnesium sulphate. Other group (Group B) will be given local infiltration with 9 ml (180 mg) of 2% lignocaine.
Study NCT05801588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T'ai Chi and Qigong Rehabilitation
Description: T'ai chi/Qigong is a multidimensional (mind, body, and spirit integrative) and multimodal (strength, flexibility, balance, posture, and light to moderate aerobic) form of exercise that is safe for persons of all ages and physical abilities. The 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation program proposed to be studied is adapted from the WaQi program, a curriculum developed by Master Yang Yang, PhD. The practice is gentle yet powerful, aiming to relieve and prevent back, neck, and hip pain. It has an online teaching module and is uniquely suited for our study population. The program requires no difficult movement transitions, but still contains all essential parts including meditation. The WaQi program has less psychological stress and physical challenge than other exercise activities because it can be performed either sitting, standing, and lying down.
Study NCT05801588 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The control arm will receive the same 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation, online live T'ai Chi and Qigong teaching module from Jan. 26, 2023 to April 17, 2023.